Combining Neuroendocrine Inhibitors in Heart Failure: Reflections on Safety and Efficacy

American Journal of Medicine

Volumn 120, Issue 12, 2007, Pages

  Jneid, Hani ^a   Moukarbel, George V ^a   Dawson, Bart ^b   Hajjar, Roger J ^a   Francis, Gary S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aldosterone; Angiotensin; Beta blocker; Heart failure; Neuroendocrine; Systolic dysfunction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; METOPROLOL; PLACEBO; SPIRONOLACTONE; VALSARTAN;

ADRENERGIC SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPERKALEMIA; HYPOTENSION; RENAL INSUFFICIENCY;

EID: 36448958734     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.02.029     Document Type: Review

References (40)

1. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 21 (1996) 1349-1355
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 9146 (1999) 9-13
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 9169 (1999) 2001-2007
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 5 (1991) 293-302
5. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
6. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 8875 (1993) 821-828
7. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 23 (2001) 1667-1675
8. McKelvie R.S., Rouleau J.L., White M., et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 24 19 (2003) 1727-1734
9. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (2003) 1893-1906
10. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 9386 (2003) 759-766
11. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 9386 (2003) 767-771
12. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 9386 (2003) 777-781
13. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 9386 (2003) 772-776
14. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
15. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
16. Francis G.S., and Tang W.H. Pathophysiology of congestive heart failure. Rev Cardiovasc Med 4 Suppl 2 (2003) S14-S20
17. Mann D.L., Kent R.L., Parsons B., and Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85 2 (1992) 790-804
18. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 23 (2001) 1689-1697
19. Sharma J.N. Does the kinin system mediate in cardiovascular abnormalities?. An overview. J Clin Pharmacol 43 11 (2003) 1187-1195
20. Matsusaka T., and Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 59 (1997) 395-412
21. Cruden N.L., Witherow F.N., Webb D.J., et al. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 24 6 (2004) 1043-1048
22. Falkenstein E., Christ M., Feuring M., and Wehling M. Specific nongenomic actions of aldosterone. Kidney Int 57 4 (2000) 1390-1394
23. Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 6 5 (2004) 539-545
24. Lee A.F., MacFadyen R.J., and Struthers A.D. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1 4 (1999) 401-406
25. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 8 (1999) 577-585
26. Zipes D.P., and Wellens H.J. Sudden cardiac death. Circulation 98 21 (1998) 2334-2351
27. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 6 (2004) 543-551
28. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
29. Svensson M., Gustafsson F., Galatius S., et al. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 327 7424 (2003) 1141-1142
30. Wrenger E., Muller R., Moesenthin M., et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 327 7407 (2003) 147-149
31. Jarman P.R., Kehely A.M., and Mather H.M. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J 71 839 (1995) 551-552
32. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 13 (2004) 1296-1305
33. McAlister F.A., Ezekowitz J., Tonelli M., and Armstrong P.W. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109 8 (2004) 1004-1009
34. Fang J.C. Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?. Circulation 112 16 (2005) 2380-2382
35. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 10 (2002) 1623-1629
36. Willenheimer R., van Veldhuisen D.J., Silke B., et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 16 (2005) 2426-2435
37. Heart Failure Society of America 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 1 (2006) e1-e122
38. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 9215 (2000) 1582-1587
39. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 9335 (2002) 752-760
40. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 20 (2004) 2049-2057